Context Therapeutics (CNTX) Competitors $1.02 -0.07 (-6.42%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CNTX vs. TSHA, ALMS, AKBA, CYRX, NGNE, PROC, DSGN, VYGR, BTMD, and CTNMShould you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Taysha Gene Therapies (TSHA), Alumis (ALMS), Akebia Therapeutics (AKBA), Cryoport (CYRX), Neurogene (NGNE), Procaps Group (PROC), Design Therapeutics (DSGN), Voyager Therapeutics (VYGR), biote (BTMD), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry. Context Therapeutics vs. Taysha Gene Therapies Alumis Akebia Therapeutics Cryoport Neurogene Procaps Group Design Therapeutics Voyager Therapeutics biote Contineum Therapeutics Taysha Gene Therapies (NASDAQ:TSHA) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, community ranking, media sentiment, risk, profitability, earnings and institutional ownership. Which has more risk & volatility, TSHA or CNTX? Taysha Gene Therapies has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500. Does the media refer more to TSHA or CNTX? In the previous week, Taysha Gene Therapies and Taysha Gene Therapies both had 1 articles in the media. Context Therapeutics' average media sentiment score of 1.94 beat Taysha Gene Therapies' score of 0.60 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders and institutionals hold more shares of TSHA or CNTX? 77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 2.7% of Taysha Gene Therapies shares are held by company insiders. Comparatively, 3.0% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate TSHA or CNTX? Taysha Gene Therapies currently has a consensus target price of $6.63, suggesting a potential upside of 258.11%. Context Therapeutics has a consensus target price of $6.80, suggesting a potential upside of 566.67%. Given Context Therapeutics' higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Taysha Gene Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in TSHA or CNTX? Taysha Gene Therapies received 86 more outperform votes than Context Therapeutics when rated by MarketBeat users. Likewise, 77.04% of users gave Taysha Gene Therapies an outperform vote while only 72.00% of users gave Context Therapeutics an outperform vote. CompanyUnderperformOutperformTaysha Gene TherapiesOutperform Votes10477.04% Underperform Votes3122.96% Context TherapeuticsOutperform Votes1872.00% Underperform Votes728.00% Which has higher earnings and valuation, TSHA or CNTX? Context Therapeutics has lower revenue, but higher earnings than Taysha Gene Therapies. Context Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTaysha Gene Therapies$9.92M38.24-$111.57M$0.632.94Context TherapeuticsN/AN/A-$23.96M-$0.91-1.12 Is TSHA or CNTX more profitable? Context Therapeutics has a net margin of 0.00% compared to Taysha Gene Therapies' net margin of -229.67%. Context Therapeutics' return on equity of -58.76% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Taysha Gene Therapies-229.67% -106.36% -49.16% Context Therapeutics N/A -58.76%-55.80% SummaryTaysha Gene Therapies beats Context Therapeutics on 8 of the 15 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTX vs. The Competition Export to ExcelMetricContext TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$76.50M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-1.1210.5991.3417.19Price / SalesN/A195.381,116.63116.80Price / CashN/A57.1642.5837.86Price / Book1.385.104.794.78Net Income-$23.96M$151.51M$120.07M$225.60M7 Day Performance-26.62%-2.14%-1.90%-1.24%1 Month Performance-32.00%-3.13%11.43%3.06%1 Year Performance-8.11%11.51%30.59%16.50% Context Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTXContext Therapeutics2.9773 of 5 stars$1.02-6.4%$6.80+566.7%+1.0%$76.50MN/A-1.127Positive NewsGap DownTSHATaysha Gene Therapies3.6226 of 5 stars$1.99-3.9%$6.63+232.9%+30.3%$407.83M$15.45M3.29180ALMSAlumisN/A$8.60+2.5%$26.83+212.0%N/A$406.11MN/A0.00N/AAnalyst ForecastLockup ExpirationNews CoveragePositive NewsAKBAAkebia Therapeutics3.3979 of 5 stars$1.85-0.3%$7.50+306.5%+52.5%$402.54M$169.88M-8.15167News CoverageCYRXCryoport3.0208 of 5 stars$7.72+0.4%$12.50+61.9%-49.8%$381.61M$226.11M-2.321,170Analyst ForecastGap DownNGNENeurogene3.74 of 5 stars$24.81+5.5%$60.83+145.2%N/A$368.55M$925,000.000.0090PROCProcaps Group0.891 of 5 stars$3.24+34.4%N/A-20.3%$365.54M$414.10M5.105,500News CoverageGap UpHigh Trading VolumeDSGNDesign Therapeutics0.926 of 5 stars$6.30+12.5%$7.00+11.1%+143.2%$356.71MN/A-7.1840News CoveragePositive NewsVYGRVoyager Therapeutics4.6047 of 5 stars$6.52+4.0%$17.00+160.7%-27.6%$356.19M$250.01M8.83100BTMDbiote3.2446 of 5 stars$6.49+1.9%$9.11+40.4%+20.8%$352.65M$193.06M24.77194Positive NewsGap UpCTNMContineum Therapeutics1.9464 of 5 stars$13.48-3.9%$29.25+117.0%N/A$347.49M$50M0.0031News Coverage Related Companies and Tools Related Companies TSHA Alternatives ALMS Alternatives AKBA Alternatives CYRX Alternatives NGNE Alternatives PROC Alternatives DSGN Alternatives VYGR Alternatives BTMD Alternatives CTNM Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CNTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
